News & Updates

Show Multimedia Only

Ruxolitinib cream shows benefit in patients with AD, regardless of age

15 Mar 2025 by

Twice-daily application of ruxolitinib cream monotherapy appears effective and well tolerated in the treatment of mild-to-moderate atopic dermatitis (AD), regardless of age, based on a pooled analysis of three phase III trials presented at AAAAI/WAO 2025.

Ruxolitinib cream shows benefit in patients with AD, regardless of age

15 Mar 2025

High-dose vitamin D may quell clinically isolated syndrome of MS

14 Mar 2025 by

Supplementation with high-dose vitamin D in patients with clinically isolated syndrome typical for multiple sclerosis (MS) helps lower disease activity, as shown in the D-Lay MS trial.

High-dose vitamin D may quell clinically isolated syndrome of MS

14 Mar 2025

Twice-yearly depemokimab safe, effective in CRSwNP

14 Mar 2025 by

Treatment with two doses of depemokimab results in sufficient concentrations to adequately control blood eosinophil counts (BEC) over 1 year, as shown in the ANCHOR 1 and 2 trials. This finding suggests sustained anti-interleukin-5 (IL-5) biological effect and impact on type 2 inflammation.

Twice-yearly depemokimab safe, effective in CRSwNP

14 Mar 2025

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

14 Mar 2025

Using tranexamic acid (TXA) appears to lessen blood loss and the need for perioperative blood transfusion (PBT) without increasing the risk of venous thromboembolism (VTE) in patients with bladder cancer undergoing radical cystectomy, reports a study.

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

14 Mar 2025

Omalizumab continues to OUtMATCH OIT in updated analysis

14 Mar 2025 by

Omalizumab remains superior to oral immunotherapy (OIT) for the treatment of multi-food allergies with fewer adverse effects in Stage 2 of the NIH*-sponsored phase III OUtMATCH** study, the first head-to-head trial comparing the two treatments.

Omalizumab continues to OUtMATCH OIT in updated analysis

14 Mar 2025

H56:IC31 vaccine of no help against TB recurrence

14 Mar 2025

For individuals who completed treatment for pulmonary tuberculosis (TB), vaccination with H56:IC31 does not appear to reduce the risk of disease recurrence, according to a phase 2b trial.

H56:IC31 vaccine of no help against TB recurrence

14 Mar 2025

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

$Upadacitinib for refractory CD safe, effective in real-world use$

Upadacitinib for refractory CD safe, effective in real-world use

13 Mar 2025

In a real-world cohort of patients with highly refractory Crohn’s disease (CD), upadacitinib treatment prompted clinical response in most and steroid-free clinical remission in half, while having an acceptable safety profile.

Upadacitinib for refractory CD safe, effective in real-world use

13 Mar 2025

SG sees drop in paediatric pneumococcal disease burden

13 Mar 2025 by

The introduction of pneumococcal conjugate vaccines (PCV) into Singapore's National Childhood Immunisation Schedule (NCIS) has reduced the incidence of invasive pneumococcal disease (IPD) in children by nearly a third, as reported in a study.

SG sees drop in paediatric pneumococcal disease burden

13 Mar 2025

Young adults unaware of male HPV infection, vaccine benefits

13 Mar 2025 by

Awareness about human papillomavirus (HPV) infection in males and the benefits of vaccination on both genders is low among young adults, reveals a Singapore study.

Young adults unaware of male HPV infection, vaccine benefits

13 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Ruxolitinib cream shows benefit in patients with AD, regardless of age

Ruxolitinib cream shows benefit in patients with AD, regardless of age

High-dose vitamin D may quell clinically isolated syndrome of MS

High-dose vitamin D may quell clinically isolated syndrome of MS

Twice-yearly depemokimab safe, effective in CRSwNP

Twice-yearly depemokimab safe, effective in CRSwNP

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

Omalizumab continues to OUtMATCH OIT in updated analysis

Omalizumab continues to OUtMATCH OIT in updated analysis

H56:IC31 vaccine of no help against TB recurrence

H56:IC31 vaccine of no help against TB recurrence

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Upadacitinib for refractory CD safe, effective in real-world use

Upadacitinib for refractory CD safe, effective in real-world use

SG sees drop in paediatric pneumococcal disease burden

SG sees drop in paediatric pneumococcal disease burden

Young adults unaware of male HPV infection, vaccine benefits

Young adults unaware of male HPV infection, vaccine benefits